Clinical trial
PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent…
NCT00116792 · Gold, Herman K., MD, Other · Unknown status
Key facts
| NCT number | NCT00116792 |
|---|---|
| Title | PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions |
| Official title | PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions |
| Lead sponsor | Gold, Herman K., MD, Other |
| Collaborators | Guidant Corporation Industry |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease, Diabetes Mellitus |
| Intervention type | Procedure |
| Interventions | Percutaneous Coronary Intervention (PCI) |
| Enrollment | 120 |
| Start date | Mar 1, 2004 |
| First posted | Jul 1, 2005 |
| Last update posted | May 17, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: